Perspective

Split Viewer

Korean J Hematol 2012; 47(4):

Published online December 31, 2012

https://doi.org/10.5045/kjh.2012.47.4.241

© The Korean Society of Hematology

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?

Chul Won Jung, M.D. Ph.D.

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Perspective

Korean J Hematol 2012; 47(4): 241-242

Published online December 31, 2012 https://doi.org/10.5045/kjh.2012.47.4.241

Copyright © The Korean Society of Hematology.

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?

Chul Won Jung, M.D. Ph.D.

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download